SS-31, MOTS-c, & NAD+The Mitochondrial Peptide Stack for Energy & Youthful Restoration

The MITT-Stack (Mitochondrial Integration & Transformation Triad) combines three compounds that target different aspects of mitochondrial dysfunction: SS-31 repairs the membrane, MOTS-c retrains metabolic signaling, and NAD+ restores redox currency. Together they address the root cause of cellular energy failure rather than masking symptoms.

This matters because most chronic fatigue, metabolic inflexibility, and slow recovery trace back to mitochondria that can't produce enough ATP. Traditional approaches treat downstream effects; the MITT-Stack targets the organelles themselves.

These peptides lack FDA approval for most indications. SS-31 (Elamipretide) has Phase 2 data in cardiomyopathies; MOTS-c and NAD+ are used off-label. Work with a licensed clinician.

At a Glance

• SS-31: Repairs cardiolipin in mitochondrial membranes, reducing electron leak and ROS
• MOTS-c: Activates AMPK/PGC-1α signaling for metabolic flexibility and mitochondrial biogenesis
• NAD+: Restores redox currency for sirtuins, DNA repair, and energy metabolism
• Protocol: 12-week cycles with loading and maintenance phases
• Applications: Fatigue, metabolic dysfunction, injury recovery support, longevity

What Is a Mitochondrial Peptide Stack?

A mitochondrial peptide stack combines multiple compounds that target different aspects of mitochondrial function. Rather than relying on a single peptide, stacking addresses structure (SS-31), signaling (MOTS-c), and fuel (NAD+) simultaneously — the three axes that determine whether your mitochondria produce abundant energy or limp along in survival mode.

MOTS-c is a mitochondrial-derived peptide encoded in the 12S rRNA gene. When released during exercise or metabolic stress, it travels to the nucleus to regulate gene expression — a process called retrograde mitochondrial signaling. This exercise-mimetic effect makes MOTS-c a cornerstone of mitochondrial optimization protocols.

SS-31 (Elamipretide) targets the structural foundation: cardiolipin in the inner membrane. NAD+ provides the redox currency both peptides require to function. The MOTS-c SS-31 stack, combined with NAD+, creates a complete system that repairs existing mitochondria while building new, metabolically intelligent copies.

The Three Axes of Mitochondrial Health

The MITT-Stack addresses all three axes simultaneously.

Component 1: SS-31 — Membrane Repair

SS-31 (also called Elamipretide) is a tetrapeptide that binds to cardiolipin in the inner mitochondrial membrane. Cardiolipin anchors the electron transport chain; when it oxidizes, electrons leak, ATP production drops, and reactive oxygen species (ROS) spike.

Mechanism: SS-31 stabilizes cardiolipin, tightening respiratory supercomplexes and reducing ROS production by up to 60% in preclinical models.

Translation: More ATP from each oxygen molecule, less oxidative damage, rapid improvement in fatigue.

Evidence: Phase 2 trials in Barth syndrome and cardiomyopathies show improved ATP kinetics and functional endpoints.

Component 2: MOTS-c — Metabolic Reprogramming

MOTS-c is a mitochondrial-derived peptide encoded in the 12S rRNA gene that acts as an exercise mimetic. It signals from mitochondria back to the nucleus, activating metabolic adaptation pathways — a process called retrograde signaling.

Mechanism: Activates AMPK and PGC-1α, increases GLUT4 expression, improves fatty-acid oxidation, and restores insulin sensitivity. Under metabolic stress, MOTS-c translocates to the nucleus where it directly regulates gene expression related to glucose homeostasis.

Translation: Cells shift from glucose hoarding to flexible fuel use. Endurance improves, metabolic rate stabilizes, and the body responds better to caloric deficits.

Evidence: Published in Cell Metabolism (2015) by the Cohen Lab at USC, with follow-up studies confirming metabolic benefits in humans. Exercise increases circulating MOTS-c levels by up to 12-fold.

See MOTS-c Peptide Guide for complete coverage.

Component 3: NAD+ — Redox Currency

NAD+ is the central cofactor for energy metabolism, DNA repair, and sirtuin activation. Levels decline ~50% between age 20 and 50, and faster under chronic stress or inflammation.

Mechanism: Restores NAD+/NADH ratio, activates sirtuins (SIRT1–3), calms PARP overactivation, and synchronizes circadian rhythms.

Translation: Sustained energy, better sleep, deeper recovery, improved mental clarity.

Evidence: Multiple RCTs with NMN/NR precursors show tissue NAD+ elevation; IV/IM NAD+ provides higher peak levels.

See NAD+ Guide for complete coverage.

How the Components Work Together

The synergy matters more than any single component:

• SS-31 + NAD+: Efficient electron transport plus abundant redox fuel = higher ATP output without oxidative damage
• MOTS-c + NAD+: New mitochondria (from biogenesis) need charged batteries (NAD+) to function
• SS-31 + MOTS-c: Repair existing mitochondria while building new, metabolically intelligent copies

Once ATP production exceeds maintenance cost, cells stop triaging and start investing in repair: collagen renews, nerves fire cleanly, hormones regain sensitivity.

Protocol: 12-Week MITT Cycle

Cycling: 12 weeks on, 4 weeks off. Repeat twice yearly or maintain lighter cadence (SS-31 weekly, MOTS-c pulses, NAD+ 2–3×/week).

Need help preparing your peptides? See the Reconstitution Guide for step-by-step instructions.

Timeline of Effects

Applications

GLP-1 Fatigue: The Mitochondrial Bottleneck

Fatigue is the most common complaint among people on GLP-1 medications. Semaglutide fatigue, tirzepatide fatigue, ozempic fatigue, mounjaro fatigue — different drug names, same pattern. Weight loss works, but energy crashes. The forums are full of people who hit a wall around month 2–3.

Why it happens: GLP-1 agonists shift metabolism rapidly toward fat oxidation. Fat burning is more mitochondrially demanding than glucose burning. When the instruction to increase oxidation arrives at mitochondria that were already running near capacity — because of age, chronic inflammation, or baseline depletion — they can't keep up. ATP production falters under the new demand.

Why MITT helps: The stack addresses all three failure points:

• SS-31 repairs the membrane structure so electrons flow cleanly (less waste, more output)
• MOTS-c signals cells to build more mitochondria and improve fuel selection (more capacity)
• NAD+ provides the redox currency both processes require (fuel for the machinery)

The result: mitochondria can actually execute what GLP-1s are asking for. Energy stabilizes, the "wall" retreats, and weight loss continues without the fatigue tax.

Practical integration: Most practitioners add MITT after 4–6 weeks of GLP-1 therapy, when fatigue becomes noticeable. Starting MOTS-c at 5mg 2–3×/week and NAD+ support addresses the immediate bottleneck. SS-31 is added if fatigue persists or if recovery from exercise remains slow.

See Retatrutide + NAD+ Protocol for beginner implementation.

Injury recovery

The MITT-Stack provides the ATP foundation that tissue repair requires. It's typically used after vascular restoration (BPC-157/TB-500) when cellular energy becomes the limiting factor.

Longevity and anti-aging

By sustaining sirtuin activity, supporting DNA repair, and maintaining mitochondrial density, the MITT-Stack addresses the metabolic decline that underlies aging.

Side Effects and Safety

SS-31: Generally well tolerated. IV use can cause transient warmth or flushing.

MOTS-c: Early-week fatigue is common (AMPK activation adjusting metabolism). Eat adequately on training days.

NAD+: Slow injection rate to avoid chest tightness. Hydration is important.

Contraindications: Active malignancy, uncontrolled hypertension, acute infection — pause until resolved.

Monitoring: Consider baseline and month-2 checks for CMP, lipids, and hs-CRP.

FAQ

Can I run MITT without NAD+ injections?

You'll blunt the synergy. NAD+ is the currency the other peptides spend. Oral NMN/NR is an alternative but provides lower peak levels than injection.

How does MITT differ from NAD+ therapy alone?

NAD+ provides fuel but doesn't repair damaged membranes or build new mitochondria. The full MITT-Stack addresses structure (SS-31), signaling (MOTS-c), and fuel (NAD+).

Is MITT anabolic?

Not directly muscle-building, but by improving ATP production and reducing inflammation, it makes training and any growth-hormone protocol more effective.

What is the best MOTS-c and SS-31 stack dosage?

Most protocols use MOTS-c 5–10 mg and SS-31 10 mg, administered 2–3 times weekly. The MITT-Stack adds NAD+ 150–200 mg to complete the triad. See the Protocol section above for phase-specific dosing.

Can I take MOTS-c and SS-31 together on the same day?

Yes. These peptides work on different mitochondrial systems — SS-31 on membrane structure, MOTS-c on metabolic signaling — and do not compete for absorption. Many practitioners administer both in the same session alongside NAD+ infusion.

Is a MOTS-c SS-31 stack better than NAD+ alone?

NAD+ provides fuel but doesn't repair damaged membranes (SS-31's job) or stimulate new mitochondrial biogenesis (MOTS-c's job). The stack addresses root causes rather than just energy currency. Think of it this way: NAD+ is like putting premium fuel in a car, but the mitochondrial peptide stack also fixes the engine and adds a turbocharger.

Related Topics

• NAD+ Guide — complete NAD+ overview
• BPC-157 + TB-500 for Injury Recovery — vascular restoration (often precedes MITT)
• Retatrutide + NAD+ Protocol — GLP-1 with metabolic support

References

SS-31 (Elamipretide)

• Szeto HH. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. Br J Pharmacol. 2014;171(8):2029-2050. doi:10.1111/bph.12461
• Phase 2 trials in Barth syndrome and cardiomyopathies demonstrate improved ATP kinetics and functional endpoints

MOTS-c

• Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-454. doi:10.1016/j.cmet.2015.02.009
• Kim KH, Son JM, Benayoun BA, Lee C. The mitochondrial-encoded peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression. Cell Metab. 2018;28(3):516-524. doi:10.1016/j.cmet.2018.06.008

NAD+

• Rajman L, Chwalek K, Sinclair DA. Therapeutic potential of NAD-boosting molecules: the in vivo evidence. Cell Metab. 2018;27(3):529-547. doi:10.1016/j.cmet.2018.02.011
• Multiple RCTs with NMN/NR precursors demonstrate tissue NAD+ elevation and functional improvements

Educational content only. Some compounds discussed are FDA-approved medications; others are research peptides without FDA approval — not due to safety concerns, but because unpatentable compounds cannot justify the required trial investment. Work with a qualified healthcare provider before using any protocol.